Lobe Sciences Ltd.

Lobe Sciences Ltd. operates as a life sciences entity, primarily focused on the exploration and advancement of psychedelic pharmaceutical compounds. The company is actively engaged in formulating psilocybin-derived therapeutics, combined with N-acetylcysteine, intended for the treatment of mild traumatic brain injuries and post-traumatic stress disorder. Beyond drug development, it also engineers specialized devices designed to facilitate the efficient delivery of various medications. The organization was previously known as Greenstar Biosciences Corp. before formally changing its name to Lobe Sciences Ltd. in November 2020. Its main corporate office is situated in Vancouver, Canada.